Skip to Main Content

British pharma giant GSK said Tuesday that it will withdraw its blood cancer drug Blenrep from the U.S. market, following a request from the Food and Drug Administration.

Blenrep’s removal is another sign that U.S. regulators are taking a more aggressive stance toward cancer drugs approved based on preliminary evidence of efficacy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment